Results 71 to 80 of about 59,669 (311)

Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess the value of serum type I interferon (IFN) score in predicting clinically meaningful progression in limited cutaneous systemic sclerosis (lcSSc) using a novel composite endpoint adopted from the MINIMISE clinical trial. Methods A retrospective, longitudinal lcSSc cohort was identified within a national, multicenter observational ...
Stefano Di Donato   +9 more
wiley   +1 more source

Effect of hydroxychloroquine and azithromycin combination use in COVID-19 patients – An umbrella review

open access: yesIndian Journal of Community Medicine
Background: Hydroxychloroquine and Azithromycin combination was used rampantly in management of COVID-19 patients in different countries. Present review was conducted to evaluate the efficacy of Hydroxychloroquine and Azithromycin combination compared to
Kaushik Nag   +7 more
doaj   +1 more source

Efficacy of hydroxychloroquine in pre-exposure severe acute respiratory syndrome coronavirus 2 prophylaxis among high-risk healthcare workers: A multicenter study

open access: yesAdvanced Biomedical Research, 2023
Background: Prophylaxis could be an established strategy to potentially prevent and control infectious diseases and should be considered in the coronavirus disease 2019 (COVID-19) pandemic.
Elahe Nasri   +10 more
doaj   +1 more source

Hydroxychloroquine in lupus pregnancy [PDF]

open access: yesArthritis & Rheumatism, 2006
AbstractObjectiveHydroxychloroquine (HCQ) is often needed to manage disease activity in systemic lupus erythematosus (SLE) during pregnancy. The purpose of this study was to examine lupus activity and pregnancy outcomes in women with SLE treated or not treated with HCQ during pregnancy.MethodsThis was a prospective study of pregnancies in women with ...
Frank R. Witter   +3 more
openaire   +3 more sources

Anti‐MDA5 and anti‐SSA/Ro52 antibodies double‐positive dermatomyositis overlapping with rheumatoid arthritis‐associated interstitial lung disease: A case report

open access: yesInternational Journal of Rheumatic Diseases, Volume 25, Issue 12, Page 1437-1440, December 2022., 2022
Abstract Dermatomyositis (DM) is a poorly prognostic autoimmune disease the pathogenesis of which is multifactorial and not clearly defined. DM may be influenced by genes, environment, and immunity. The typical manifestations of DM are Gottron rash, heliotrope rash, rash on the shoulders and buttocks, erythema around fingernails, excessive keratosis of
Hong Xiong   +5 more
wiley   +1 more source

Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.

open access: yesPLoS ONE, 2020
Hydroxychloroquine has been touted as a potential COVID-19 treatment. Tocilizumab, an inhibitor of IL-6, has also been proposed as a treatment of critically ill patients.
Andrew Ip   +31 more
doaj   +1 more source

COVID‐19: Understanding the impact of anti‐hypertensive drugs and hydroxychloroquine on the ACE1 and ACE2 in lung and adipose tissue in SHR and WKY rats

open access: yesPhysiological Reports, 2023
Hypertensive individuals taking anti‐hypertensive drugs from renin‐angiotensin system inhibitors may exhibit a more severe evolution of the disease when contracting the SARS‐CoV‐2 virus (COVID‐19 disease) due to potential increases in ACE2 expression ...
Beatriz Santos Geoffroy Corrêa   +6 more
doaj   +1 more source

Efficacy of early treatment with hydroxychloroquine in people with mild to moderate COVID-19: a systematic review and meta-analysis

open access: yesArchives of Medical Science, 2021
Introduction No early treatment intervention for COVID-19 has proven effective to date. We systematically reviewed the efficacy of hydroxychloroquine as early treatment for COVID-19.
Adrian V. Hernandez   +7 more
doaj   +1 more source

Causal inference methods for small non-randomized studies: Methods and an application in COVID-19 [PDF]

open access: yesarXiv, 2020
The usual development cycles are too slow for the development of vaccines, diagnostics and treatments in pandemics such as the ongoing SARS-CoV-2 pandemic. Given the pressure in such a situation, there is a risk that findings of early clinical trials are overinterpreted despite their limitations in terms of size and design.
arxiv  

Machine Learning for Real-World Evidence Analysis of COVID-19 Pharmacotherapy [PDF]

open access: yesarXiv, 2021
Introduction: Real-world data generated from clinical practice can be used to analyze the real-world evidence (RWE) of COVID-19 pharmacotherapy and validate the results of randomized clinical trials (RCTs). Machine learning (ML) methods are being used in RWE and are promising tools for precision-medicine.
arxiv  

Home - About - Disclaimer - Privacy